The Quantellect read.As of Nov 19, 2026, 12 active firms cover United Therapeutics Corporation: 9 rate it Buy or better, 2 sit at Neutral, and 1 rate it Sell or worse, a buy consensus. Targets range widely, $321.00 to $738.00 (about 2.3x), a sign of real disagreement on valuation. The average target of $623.00 sits 8% above the current $577.55. Sentiment has cooled somewhat, with Sell ratings rising from 0 to 1 over recent months. On the fundamentals, the Street sees consensus EPS building from about $6.53 next quarter toward $31.44 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS12 active firms
Buy
Strong Buy00%
Buy975%
Neutral217%
Sell18%
Strong Sell00%
Based on 12 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$623.00
+7.9% upside
Average target across 7 active firms as of Nov 19, 2026 vs $577.55 current
Highest Target$738.00
Average Target$623.00
Lowest Target$321.00
Detailed analyst forecasts for UTHR
Showing 1–7 of 7 named analysts shown · 12 active firms in the rating projection
As of Nov 19, 2026, 9 of 12 active firms rate UTHR a Buy (2 Neutral, 1 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
UTHR EPS & revenue forecast
EPS · NEXT QUARTER
$6.53
Range $5.21 – $7.41 · 5 analysts · +12% YoY
Next period, 5 analysts expect United Therapeutics Corporation to earn $6.53 a share (range $5.21 – $7.41), versus $5.82 a year earlier. Full-year consensus is $24.96, growing to $31.44 the year after.
REVENUE · NEXT QUARTER
$790.1M
Range $688.0M – $849.7M · 5 analysts · +1% YoY
Revenue is expected to reach $790.1M (range $688.0M – $849.7M), +1.1% year-over-year. Full-year consensus is $3.3B, rising to $3.6B next year.
Top analysts covering United Therapeutics Corporation
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on UTHR.
#1
Andrew Fein
HC Wainwright & Co. · Rank #73
Buy
$660.00+14.3% to target
Overall win rate
45%
+ Follow
#2
Jessica Fye
JP Morgan · Rank #100
Buy
$695.00+20.3% to target
Overall win rate
54%
+ Follow
#3
Roger Song
Jefferies · Rank #122
Buy
$704.00+21.9% to target
Overall win rate
43%
+ Follow
#4
Jason Gerberry
B of A Securities · Rank #160
Neutral
$559.00-3.2% to target
Overall win rate
47%
+ Follow
#5
Julian Harrison
BTIG · Rank #183
Buy
$728.00+26.0% to target
Overall win rate
41%
+ Follow
UTHR stock forecast FAQ
What is UTHR's average 12-month price target?+
The 7 active firms with a live target average $623.00 for United Therapeutics Corporation over the next 12 months, ranging from a $738.00 high to a $321.00 low, as of Nov 19, 2026.
Is UTHR stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 12 active firms as of Nov 19, 2026, 9 rate it Buy or Strong Buy, 2 rate it Neutral, and 1 rate it Sell or Strong Sell.
What are the highest and lowest price targets for UTHR?+
The Street-high target is $738.00 (Wells Fargo), and the Street-low is $321.00 (Goldman Sachs). The average of all 7 active-firm targets is $623.00.
How many active Wall Street firms cover UTHR?+
12 active firms have a recognized rating on United Therapeutics Corporation as of Nov 19, 2026, and 7 active firms carry a live 12-month price target.
Who is the most accurate analyst covering UTHR?+
Among analysts who currently cover UTHR, Andrew Fein of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #73). Their current call is Buy with a $660.00 target.
What is United Therapeutics Corporation's projected EPS for next quarter?+
The consensus estimate is $6.53 per share (range $5.21 – $7.41) across 5 analysts. Full-year EPS is projected at $24.96, rising to $31.44 the following year.
How much revenue is United Therapeutics Corporation expected to report next quarter?+
Consensus revenue is $790.1M (range $688.0M – $849.7M). Full-year revenue is projected at $3.3B, growing to $3.6B next year.
Have analysts been upgrading or downgrading UTHR lately?+
As of Nov 19, 2026, 9 of 12 active firms rate UTHR a Buy (2 Neutral, 1 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their UTHR calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.